Early fast‐acting treatment strategy against generalized myasthenia gravis
Open Access
- 7 September 2016
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 55 (6) , 794-801
Abstract
Introduction: In this study we sought to clarify the effects of early fast‐acting treatment (EFT) strategies on the time course for achieving the treatment target in generalized myasthenia gravis (MG).Methods: This retrospective study of 923 consecutive MG patients analyzed 688 generalized MG patients who had received immunotherapy during the disease course. The time to first achieve minimal manifestations (MM) or better while receiving prednisolone at ≤5 mg/day for ≥6 months (MM‐or‐better‐5mg) up to 120 months after starting immunotherapy was compared between EFT and non‐EFT patients.Results: Achievement of MM‐or‐better‐5mg was more frequent and earlier in the EFT group (P = 0.0004, Wilcoxon test; P = 0.0001, log‐rank test). Multivariate Cox regression analysis calculated a hazard ratio of 1.98 (P < 0.0001) for utilization of EFT. Dosing regimens of oral steroids in EFT produced no differences in the time course.Conclusions: EFT strategies are advantageous for early achievement of MM‐or‐better‐5mg. Muscle Nerve 55: 794–801, 2017Keywords
Funding Information
- Japan MG Registry Study Group
This publication has 15 references indexed in Scilit:
- Oral corticosteroid therapy and present disease status in myasthenia gravisMuscle & Nerve, 2015
- Japanese clinical guidelines for myasthenia gravis: Putting into practiceClinical and Experimental Neuroimmunology, 2015
- Health‐related quality‐of‐life and treatment targets in myasthenia gravisMuscle & Nerve, 2014
- The MG‐QOL15 Japanese version: Validation and associations with clinical factorsMuscle & Nerve, 2012
- Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional studyBMJ Open, 2011
- Immunosuppressive therapies in myasthenia gravisAutoimmunity, 2010
- Autoimmune myasthenia gravisExpert Review of Neurotherapeutics, 2009
- Lifetime course of myasthenia gravisMuscle & Nerve, 2007
- Myasthenia gravisNeurology, 2000
- Long‐term corticosteriod treatment of myasthenia gravis: Report of 116 PatientsAnnals of Neurology, 1984